HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

At the start of this year, Scorpion had sold its mutant-selective PI3Kα inhibitor STX-478 to Lilly for up to $2.5 billion in biobucks. The deal followed a phase 1 data drop that showed STX-478 ...

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky.

Autolus' CAR-T cell therapy for a rare and aggressive form of acute lymphoblastic leukaemia (ALL), Aucatzyl, has been recommended for conditional approval in the EU. The EMA's human medicines ...

It was joined last year by Roche's Itovebi (inavolisib), the company's second candidate after its lead drug in the class (taselisib) was abandoned on safety grounds.

newsHoffmann-La Roche Limited (Roche Canada) At Roche Canada, patients and science are at the heart of everything we do. Our passion for science and our commitment to relentlessly pursuing the ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an i ...

New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more ...

The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.